Drugs / NASVAC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01374308 | Jun 2011 → Jun 2013 | chronic hepatitis B virus infection | Clinical Research Organization, Dhaka, Bangladesh | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NASVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01374308 ↗ |
| Modality | Vaccine | “The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg)...” NCT01374308 ↗ |
| Route | Intranasal | “NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally...” NCT01374308 ↗ |
| Route | Subcutaneous | “NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally...” NCT01374308 ↗ |